TrialNeuro-oncology2020
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Martin Van Den Bent et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
130 papers cite itlatest 60 shown
this paperpooled ittrialcites it